Absenteeism and productivity among employees being treated for hepatitis C

American Journal of Managed Care

Volumn 17, Issue 10, 2011, Pages 657-664

  Brook, Richard A ^a   Kleinman, Nathan L ^b   Su, Jun ^d   Corey Lisle, Patricia K ^d   Iloeje, Uchenna H ^c  

^a Retrospective Analysis   (United States)

^b Human Capital Management Services   (United States)

^c Global Health Economics and Outcomes Research   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN;

ABSENTEEISM; ADULT; ARTICLE; EMPLOYEE; EMPLOYMENT; FEMALE; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH STATUS; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; PRIORITY JOURNAL; PRODUCTIVITY; RETROSPECTIVE STUDY; SALARY; WORK DISABILITY; WORKMAN COMPENSATION;

ABSENTEEISM; ANTIVIRAL AGENTS; COST OF ILLNESS; EFFICIENCY; EMPLOYMENT; HEPATITIS C; HUMANS; INTERFERON-ALPHA; INTERFERONS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; UNITED STATES;

EID: 80054758174     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Swan T. Care and Treatment for Hepatitis C and HIV Coinfection. US Department of Health and Human Services, Health Resources and Services Administration, HIV/AIDS Bureau. http://www.cdc.gov/hepatitis/ HCV/PDFs/HRSA-HIV-HCV-2006.pdf. Published April 2006. Accessed September 8, 2009.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-714. (Pubitemid 46780630)
3. World Health Organization. Hepatitis C. Fact sheet No. 164. http:// www.who.int/mediacentre/factsheets/fs164/en/. Published June 2011. Accessed September 7, 2011.
4. US Department of Health and Human Services. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. Viral Hepatitis: A through E and Beyond. http://digestive.niddk. nih.gov/ddiseases/ pubs/viralhepatitis/ViralHepatitis-FS.pdf. Published February 2008. Accessed September 9, 2009. NIH Publication No. 08-4762.
5. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90(10):1562-1569.
6. Nguyen GC, Segev DL, Thuluvath PJ. Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension. Clin Gastroenterol Hepatol. 2007;5(9):1092-1099.
7. Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003;98(3):630-638.
8. Davis GL, Balart LA, Schiff ER, et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther. 1994;16(2):334-343. (Pubitemid 24321668)
9. Danoff A, Khan O, Wan DW, et al. Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life. Am J Gastroenterol. 2006;101(6):1235-1243.
10. Bayliss MS, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware JE Jr. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Q Life Res. 1998;7(1):39-55.
11. Perry W, Hilsabeck RC, Hassanein TI. Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci. 2008;53(2):307-321.
12. Perrillo R, Rothstein KD, Rubin R, et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat. 2004;11(2):157-165. (Pubitemid 38365767)
13. McHutchison JG, Ware JE Jr, Bayliss MS, et al. Hepatitis Interventional Therapy Group. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol. 2001;34(1):140-147. (Pubitemid 32102564)
14. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C [published correction appears in Hepatology. 2004;40(1): 269]. Hepatology. 2004;39(4):1147-1171. (Pubitemid 38428955)
15. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26(3)(suppl 1):112S-121S. (Pubitemid 27388083)
16. Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology. 2010;52(2):436-442.
17. Corey KE, Ross AS, Wurcel A, et al. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol. 2006;4(10):1278-1282. (Pubitemid 44512214)
18. Adeyemi OM. Hepatitis C in HIV-positive patients-treatment and liver disease outcomes. J Clin Gastroenterol. 2007;41(1):75-87. (Pubitemid 46045675)
19. Yeh WS, Armstrong EP, Skrepnek GH, Malone DC. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System. Pharmacotherapy. 2007;27(6):813-824. (Pubitemid 46849425)
20. Seal KH, Currie SL, Shen H, et al.; VA HCV-001 Study Group. Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter? J Clin Gastroenterol. 2007;41(2):199-205. (Pubitemid 46148663)
21. Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/ medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101(10): 2254-2262. (Pubitemid 44477552)
22. Anand BS, Currie S, Dieperink E, et al.; VA-HCV-001 Study Group. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology. 2006;130(6):1607-1616. (Pubitemid 43668853)
23. Brook RA, Kleinman NL, Choung RS, Melkonian AK, Smeeding JE, Talley NJ. Functional dyspepsia impacts absenteeism and direct and indirect costs. Clin Gastroenterol Hepatol. 2010;8(6):498-503.
24. Brook RA, Kleinman NL, Rajagopalan K. Employee costs before and after treatment initiation for bipolar disorder. Am J Manag Care. 2007;13(4):179-186. (Pubitemid 46608581)
25. Brook RA, Wahlqvist P, Kleinman NL, Wallander MA, Campbell SM, Smeeding JE. Cost of gastro-oesophageal reflux disease to the employer: a perspective from the United States. Aliment Pharmacol Ther. 2007;26(6):889-898. (Pubitemid 47346705)
26. Employee Benefits Security Administration, US Department of Labor. Fact sheet. The Health Insurance Portability and Accountability Act (HIPAA). http://www.dol.gov/ebsa/newsroom/fshipaa.html. Published December 2004. Accessed February 29, 2008.
27. Bureau of Labor Statistics, US Department of Labor. Consumer Price Index: All Urban Consumers (Current Series). http://data.bls. gov/PDQ/outside.jsp? survey=cu. Published August 2009. Accessed September 9, 2009.
28. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ. 1999;18(2):153-171. (Pubitemid 29052479)
29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
30. Wright M, Grieve R, Roberts J, Main J, Thomas HC; UK Mild Hepatitis C Trial Investigators. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess. 2006;10(21):1-113, iii.
31. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002-June 10-12, 2002. Hepatology. 2002;36(5)(suppl 1):S3-S20.